Analyst Briefing to be Held in New York on September 22, 2005
WATERTOWN, Mass., Sept. 7 /PRNewswire-FirstCall/ -- Panacos
Pharmaceuticals, Inc. (Nasdaq: PANC) ("Panacos" or "the Company") today
announced that it will hold a meeting for invited analysts and investment
professionals on Thursday, September 22, 2005 from 8:00 am to 10:00 am at the
St. Regis Hotel, Two East 55th Street, New York, NY 10022. A public webcast
of the presentations will also begin at 8:00 am EDT on the Investors page of
http://www.panacos.com.
At the meeting, data will be presented from the Company's recently
completed Phase 2a study of PA-457, the first in a new class of HIV drugs
discovered by the Company called maturation inhibitors. The meeting will
bring together leading researchers in HIV to review the scientific data and to
discuss clinical development strategies designed to make PA-457 available to
HIV patients.
The analyst briefing will include presentations and a panel discussion by:
* Dr. Jeffrey Jacobson, Assistant Chief and Program Director of
Infectious Diseases at Beth Israel Medical Center, New York;
* Dr. Dan Kuritzkes, Associate Professor of Medicine at Harvard Medical
School and Director of AIDS Research, Brigham & Women's Hospital;
* Dr. George Beatty, Assistant Clinical Professor, Medicine and Director,
HIV Clinical Trials Unit, UCSF Positive Health Program at San Francisco
General Hospital, investigator in the PA-457 Phase 2a trial.
A link to the live webcast of the presentations will be available on the
Company's Web site at http://www.panacos.com. The webcast link to access a
replay of the presentations will be archived and available through September
29, 2005.
About Panacos Pharmaceuticals
Panacos is developing the next generation of anti-infective products
through discovery and development of small molecule oral drugs for the
treatment of HIV and other major human viral diseases. Panacos' proprietary
discovery technologies and lead therapeutic candidate PA-457 focus on novel
targets in the virus life cycle, including virus fusion and virus maturation.
For more information on Panacos, please visit our web site at:
http://www.panacos.com.
Except for the historical information contained herein, the matters
discussed are forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. These
statements involve risks and uncertainties, such as the progress of clinical
development of PA-457, the timing of results of clinical trials, the execution
of the Company's financing plans, the potential role of PA-457 in treatment of
HIV patients, the timely availability of new products, market acceptance of
the Company's products, the impacts of competitive products and pricing,
government regulation of the Company's products, the Company's ability to
complete product development collaborations and other strategic transactions
and other risks and uncertainties set forth in the Company's filings with the
Securities and Exchange Commission. These risks and uncertainties could cause
actual results to differ materially from any forward-looking statements made
herein.
CONTACT:
Peyton Marshall
Executive Vice President & CFO
617-926-1551
pmarshall@panacos.com
SOURCE Panacos Pharmaceuticals, Inc.
 back to top
Related links:
http://www.panacos.com
CONTACT:
Peyton Marshall, Executive Vice President &
CFO of Panacos Pharmaceuticals, +1-617-926-1551,
pmarshall@panacos.com
|
